Term
| AE: peripheral neuropathy, osteomalacia, hyponatremia (SIADH) |
|
Definition
| carbamazepine, oxcarbazepine |
|
|
Term
| ADME: autoinducer, epoxide is active metabolite |
|
Definition
|
|
Term
|
Definition
|
|
Term
| indicated for trigeminal neuralgias or postherpetic neuralgia |
|
Definition
| gabapentin, pregabalin, carbamazepine |
|
|
Term
| lethal AE of carbamazepine, particularly in Asians |
|
Definition
|
|
Term
| AE: hypercholesterolemia, vitamin D deficiency, megaloblastic anemia; hyperactivity in children, depression in elderly |
|
Definition
|
|
Term
| barbituate used for essential tremor, very long half life; a metabolite is PEMA |
|
Definition
|
|
Term
| indicated for absence seizures; inhibits CaT channels |
|
Definition
|
|
Term
| inhibits Na channels and Glu release; indicated for all seizures and bipolar disorder |
|
Definition
|
|
Term
|
Definition
| GABAergic, inhibits Na channels, inhibits CaT channels |
|
|
Term
|
Definition
| alopecia, weight gain; pancreatic, hepatic failure; blood dyscrasias, rash |
|
|
Term
| all epileptics are teratogenic; which one is the most teratogenic? |
|
Definition
|
|
Term
| antiepileptic that inhibits P450 |
|
Definition
|
|
Term
|
Definition
| BZD, ethosuximide, lamotrigine, levetiracetam, tiagabine, zonisamide |
|
|
Term
|
Definition
| GABAergic, inhibits Na channels, inhibits carbonic anhdrase, inhibits AMPA receptors |
|
|
Term
|
Definition
| cognitive impairment, weight loss, kidney stones; nausea, sedation, ataxia, paresthesias, acute angle glaucoma, hyperchloremic non-anion gap metabolic acidosis |
|
|
Term
| primarily renal metabolism (3) |
|
Definition
| gabapentin, topiramate, levetiracetam |
|
|
Term
| AE: aggression, agitation, sedation, dizziness, blood dyscrasias; adjunct for all seizures; renal excretion |
|
Definition
|
|
Term
| MOA: inhibits GABA uptake |
|
Definition
|
|
Term
| adjunct for partial seizures (4) |
|
Definition
| gabapentin, pregabalin, zonisamide, lacosamide |
|
|
Term
| AE: labile and hostile children |
|
Definition
|
|
Term
| AE: weight loss, kidney stones, cognitive impairment, oligohydrosis, metabolic acidosis, agitation, blood dyscrasias, hepatotoxicity, rash |
|
Definition
zonisamide
(similar to topiramate except for bolded) |
|
|
Term
| AE: ataxia, dizziness, syncope, headache, diplopia |
|
Definition
|
|
Term
| most is protein bound (4) |
|
Definition
| phenytoin, lamotrigine, barbituates, tiagabine |
|
|
Term
| can be used for all seizures (4) |
|
Definition
| BZDs, lamotrigine, valproate, topiramate |
|
|
Term
| anesthetic that is particularly arrhythmogenic and flammable, high risk of malignant hyperthermia |
|
Definition
|
|
Term
| very high MAC, not a vapor |
|
Definition
|
|
Term
| MOA of inhaled anesthetics (2) |
|
Definition
| increases GABA and Gly release presynaptically; decreases sensitivity of NMDA receptors postsynaptically |
|
|
Term
| anesthetic that is a bronchodilator, does not change systemic vascular resistance |
|
Definition
|
|
Term
| ether that causes seizures |
|
Definition
|
|
Term
| ether indicated for children, causes less airway irritation |
|
Definition
|
|
Term
| MOA: keeps GABA channel open longer, GABA-independent |
|
Definition
|
|
Term
| AE: CNS depressant, respiratory depression; decreases CO but not change in PVR; indicated for anesthesia in brain trauma |
|
Definition
|
|
